FDA Grants Orphan Drug Status to Cellect's ApoGraft(TM) for Acute GvHD and Chronic GvHD

ApoGraft™ aims to solve Bone Marrow Transplantation (BMT) and other transplant rejection associated diseases Cellect's CEO, Dr. Shai Yarkoni commented "We may provide the answer to a great unmet clinical need causing severe morbidity and death in t... Regenerative Medicine, FDA Cellect Biotechnology, ApoGraft, graft versus host disease, stem cell
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news